Company Zentek Ltd.

Equities

ZEN

CA98942X1024

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly revenue - Rate of surprise

Sector Other Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 10:50:28 14/05/2024 pm IST			5-day change	1st Jan Change
1.53 ^CAD	+0.66%		+4.79%	+5.52%

03/05	Zentek Ltd. Announces Board and Management Changes	CI
25/04	Zentek Ltd. Provides ZenGUARD Business Update	CI

Zentek Ltd. is a Canada-based graphene technology company. The principal business of the Company is to develop opportunities in the graphene and related nano-materials industry based on its intellectual property, patents and unique Albany graphite. The Company is focused on the research, development, and commercialization of graphene-based products. The Company's technology helps filter and deactivate pathogens to reduce the risk of transmission. The Company is focused on commercializing ZenGUARD, which is a hydrophilic, water attracting coating that adsorbs bacteria and virus-laden aerosols and deactivates them, increasing public safety, and reducing the risk of transmission of COVID and other pathogens. The Company is developing a graphene-based fuel additive that can reduce greenhouse gas (GHG) emissions from diesel and bio-diesel fuels. The Companyâs developments include Aptamers & Rapid Detection and Graphene-Oxide Synthesis & Graphene Synthesis.

Number of employees: 29

CAD in Million	2021	Weight	2022	Weight	Delta
Nano-graphite and Graphene Materials 100.0 %	0	nan %	0	100.0 %	-

CAD in Million	2021	Weight	2022	Weight	Delta
Canada 100.0 %	0	nan %	0	100.0 %	-

Managers	Title	Age	Since
Gregory Fenton CEO	Chief Executive Officer	-	11/18/11
Wendy Ford DFI	Director of Finance/CFO	-	16/22/16
Adam MacIntosh CTO	Chief Tech/Sci/R&D Officer	-	-
Colin van der Kuur CTO	Chief Tech/Sci/R&D Officer	-	04/20/04
Francis Dubé BRD	Director/Board Member	-	11/18/11
Nick Hansford PRN	Corporate Officer/Principal	-	01/21/01
Ryan Shacklock PRN	Corporate Officer/Principal	-	-
Monique Manaigre LAW	General Counsel	-	01/18/01
James Jordan PRN	Corporate Officer/Principal	-	01/16/01

Members of the board	Title	Age	Since
Ilse Treurnicht BRD	Director/Board Member	-	05/22/05
John Snisarenko BRD	Director/Board Member	61	05/23/05
Francis Dubé BRD	Director/Board Member	-	11/18/11
Eric Wallman CHM	Chairman	-	11/18/11
Gregory Fenton CEO	Chief Executive Officer	-	11/18/11
Lisa Sim BRD	Director/Board Member	-	01/23/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	100,819,577	94,840,283 ( 94.07 %)	0	94.07 %

Name	Equities	%	Valuation
Gregory Fenton 2.829 %	2,851,780	2.829 %	3 M $
Francis Dubé 0.8901 %	897,423	0.8901 %	960 243 $
Brian Bosse 0.6041 %	609,086	0.6041 %	651 722 $
Scotia Capital, Inc. 0.4434 %	447,070	0.4434 %	478 365 $
Eric Wallman 0.4021 %	405,385	0.4021 %	433 762 $
Colin van der Kuur 0.2322 %	234,056	0.2322 %	250 440 $
Peter Wood 0.1660 %	167,348	0.1660 %	179 062 $
RBC Dominion Securities, Inc. 0.0821 %	82,799	0.0821 %	88 595 $
BMO Bank NA (Investment Management) 0.0671 %	67,666	0.0671 %	72 403 $
CIBC World Markets, Inc. 0.0368 %	37,100	0.0368 %	39 697 $

Zentek Ltd.

24 Corporate Court

N1G 5G5, Guelph

+844-730-9822

http://www.zentek.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
ZENTEK LTD.	+5.52%	11Cr
MODERNA, INC.	+28.42%	4.82TCr
IQVIA HOLDINGS INC.	-0.23%	4.17TCr
LONZA GROUP AG	+43.45%	4.1TCr
CELLTRION, INC.	-5.26%	2.88TCr
ICON PUBLIC LIMITED COMPANY	+10.83%	2.56TCr
ALNYLAM PHARMACEUTICALS, INC.	-22.70%	1.9TCr
BIO-TECHNE CORPORATION	+8.54%	1.29TCr
MEDPACE HOLDINGS, INC.	+29.75%	1.2TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.97%	1.18TCr

Other Biotechnology & Medical Research